{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:02:02Z","timestamp":1785589322296,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.schres.2023.10.028","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T23:18:10Z","timestamp":1699744690000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brief commentary: Under-recognition of underuse of clozapine in treating psychotic symptoms in Parkinson's disease"],"prefix":"10.1016","author":[{"given":"Joseph H.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.schres.2023.10.028_bb0005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/0269881119855995","article-title":"Prevalence of treatment resistant psychosis in the community","volume":"33","author":"Beck","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.10.028_bb0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mds.27256","article-title":"Prevalence and indications for antipsychotic use in Parkinson\u2019s disease","volume":"33","author":"Bower","year":"2018","journal-title":"Mov. Dis."},{"issue":"4","key":"10.1016\/j.schres.2023.10.028_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1176\/appi.ps.201500493","article-title":"An initiative to improve clozapine prescribing in New York State","volume":"67","author":"Carruthers","year":"2016","journal-title":"Psychiatr. Serv."},{"issue":"10","key":"10.1016\/j.schres.2023.10.028_bb0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jagp.2020.01.193","article-title":"Risk of mortality associated with atypical antipsychotic use: a national cohort study of older adults with depression and Parkinson\u2019s disease","volume":"28","author":"Chekani","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"99160","key":"10.1016\/j.schres.2023.10.028_bb0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomized, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2023.10.028_bb0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.parkreldis.2010.11.019","article-title":"Managing idiopathic Parkinson\u2019s disease in patients with schizophrenic disorders","volume":"17","author":"Friedman","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/j.schres.2023.10.028_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson\u2019s disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"1","key":"10.1016\/j.schres.2023.10.028_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000491","article-title":"Absolute agranulocytosis after 9 weeks on clozapine 25 mg daily","volume":"45","author":"Friedman","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2023.10.028_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/WNF.0000000000000510","article-title":"Clozapine use in a movement disorders clinic","volume":"45","author":"Friedman","year":"2022","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.10.028_bb0050","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","article-title":"Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease","volume":"48","author":"Friedman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.schres.2023.10.028_bb0055","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson\u2019s disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.schres.2023.10.028_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091545","article-title":"An eight year clinic experience with clozapine use in a Parkinson\u2019s Disease clinic setting","volume":"9","author":"Hack","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.schres.2023.10.028_bb0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.07.021","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis","volume":"78","author":"Iketani","year":"2020","journal-title":"Park. Rel. Disord."},{"issue":"7","key":"10.1016\/j.schres.2023.10.028_bb0070","first-page":"449","article-title":"There is room for improvement in the rate of clozapine use among patients with schizophrenia in Israel","volume":"158","author":"Krivoy","year":"2019","journal-title":"Jul"},{"issue":"13","key":"10.1016\/j.schres.2023.10.028_bb0075","article-title":"Underuse of recommended treatments among people living with treatment-resistant psychosis","volume":"9","author":"Lappin","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.028_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","article-title":"Falls and fractures in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin vs atypical anti-psychotics: a cohort study","volume":"9","author":"Layton","year":"2022","journal-title":"Drugs-Real World Outcome"},{"key":"10.1016\/j.schres.2023.10.028_bb0085","series-title":"Presented at the 2022 American Society of Clinical Psychopharmacology (ASCP); May 31, 2022. Scottsdale, AZ","article-title":"Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson\u2019s disease-related psychosis","author":"Layton","year":"2022"},{"issue":"12","key":"10.1016\/j.schres.2023.10.028_bb0090","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-014-1772-0","article-title":"Clozapine serum concentrations in dopamimetic psychosis in Parkinson\u2019s disease and related disorders","volume":"70","author":"Lutz","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.10.028_bb0095","first-page":"39","article-title":"Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson\u2019s disease. A high potency effect of clozapine","volume":"12","author":"Meltzer","year":"1995","journal-title":"Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.schres.2023.10.028_bb0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","article-title":"Low continuation of antipsychotic therapy in Parkinson disease-intolerance, ineffectiveness, or inertia?","volume":"21","author":"Nguyen","year":"2021","journal-title":"BMC Neurol."},{"issue":"10","key":"10.1016\/j.schres.2023.10.028_bb0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41537-023-00353-0","article-title":"What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians","volume":"9","author":"Oloyede","year":"2023","journal-title":"Schizophrenia (Heidelb)"},{"issue":"8","key":"10.1016\/j.schres.2023.10.028_bb0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.schres.2023.10.028_bb0115","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40120-022-00388-y","article-title":"Screening, diagnosis and management of Parkinson\u2019s disease psychosis: recommendations, from an expert panel","volume":"11","author":"Pahwa","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.schres.2023.10.028_bb0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease\u202f: a randomised placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.10.028_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson\u2019s disease patients:a double blind labeled study of 3 months duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.schres.2023.10.028_bb0130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for the diagnosis of psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.schres.2023.10.028_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.07.004","article-title":"Can clozapine be used for treatment-refractory behavioral and psychological symptoms in dementia patients?","author":"Schulte","year":"2023","journal-title":"Schiz. Res."},{"key":"10.1016\/j.schres.2023.10.028_bb0140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.schres.2023.10.028_bb0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ps.201600041","article-title":"Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program","volume":"68","author":"Tang","year":"2017","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2023.10.028_bb0150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"The Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.schres.2023.10.028_bb0155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson\u2019s disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.schres.2023.10.028_bb0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/acps.12344","article-title":"Clozapine use pattern in persons with and without treatment for Parkinson\u2019s disease in real-world conditions: a naturalistic study in a community based sample","volume":"130","author":"Verdoux","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2023.10.028_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2617","article-title":"Clozapine prescribing practice and trends in Qatar. First national observational study","volume":"12","author":"Wadoo","year":"2022","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.schres.2023.10.028_bb0170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.10.028_bb0175","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.5498\/wjp.v12.i9.1127","article-title":"Emerging role of psychosis in Parkinson\u2019s disease: from clinical relevance to molecular mechanisms","volume":"12","author":"Zhang","year":"2022","journal-title":"World J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:42:54Z","timestamp":1700264574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S0920996423003894"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.028","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief commentary: Under-recognition of underuse of clozapine in treating psychotic symptoms in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}